Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) is scheduled to be releasing its earnings data before the market opens on Wednesday, November 1st. Analysts expect Sunesis Pharmaceuticals to post earnings of ($0.41) per share for the quarter.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.35. During the same period in the prior year, the business posted ($0.12) earnings per share. On average, analysts expect Sunesis Pharmaceuticals to post $-1.61 EPS for the current fiscal year and $-1.39 EPS for the next fiscal year.

Shares of Sunesis Pharmaceuticals, Inc. (SNSS) opened at 1.85 on Wednesday. The firm has a 50-day moving average price of $2.11 and a 200 day moving average price of $2.68. The company’s market cap is $43.50 million. Sunesis Pharmaceuticals, Inc. has a 1-year low of $1.82 and a 1-year high of $4.45.

Several equities analysts have commented on SNSS shares. Zacks Investment Research raised shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research report on Thursday, August 24th. Cantor Fitzgerald reissued a “hold” rating and set a $3.00 target price on shares of Sunesis Pharmaceuticals in a research report on Wednesday, September 27th. Finally, ValuEngine cut shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

A hedge fund recently raised its stake in Sunesis Pharmaceuticals stock. Vanguard Group Inc. grew its position in shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 4.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 605,759 shares of the biopharmaceutical company’s stock after buying an additional 23,819 shares during the quarter. Vanguard Group Inc. owned 2.58% of Sunesis Pharmaceuticals worth $1,635,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 57.56% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.